Vaccine Experience and Facilities

CTI’s Clinical Research Center (CTI CRC) is a vaccine-experienced clinical research unit in Cincinnati, OH that has been conducting clinical trials for more than 20 years, and has completed over 900 trials across all phases of development.  The team has contributed to multiple vaccine trials, including work in pandemic environments during the H1N1 (swine flu) outbreak, where the team conducted two Phase II trials and enrolled over 100 subjects in ~24 hours, and the H5N1 (bird flu) outbreak, where the Phase I trial went through an FDA audit with no 483s issued to the site. Additionally, the unit has collaborated with large pharmaceutical companies and emerging biopharmaceutical companies as part of trials resulting in vaccine approvals in areas including HPV, influenza, meningococcal group B, shingles, and swine flu. The CRC has completed 15 recent vaccine trials with a 92% subject retention rate.

The CTI CRC is part of a larger, global clinical research organization (CRO), which has been specializing in complex programs and critically-ill patient populations for three decades and is currently working on more than 15 global COVID-19 programs. CTI's infectious disease experience here and more about our work with COVID-19 initiatives here.

The CTI CRC provides full-service support solutions, including an onsite processing laboratory and data-related services. Investigators are board-certified, and research coordinators are versatile and well trained.

The CRC has updated its processes and procurement in this COVID-19 time, including:

  • Additional procurement of personal protective equipment (PPE)
  • Additional procurement of disinfectant and hand sanitizer
  • Remote check-in from the parking lot, including taking subject’s temperature
  • Social distancing with employees and subjects within the CRC
  • Processes and schedules for disinfecting

The CTI CRC houses a 30-bed clinical research unit with state-of-the-art equipment. The facility layout lends itself to conducting studies in the COVID-19 environment, offering separate patient units that are ideal for isolating subjects.  The CTI CRC is physically adjacent to a college campus, and close to many major hospitals, resulting in the potential for patient referrals, an extensive principal investigator (PI) network, and a large database of both normal healthy volunteers (NHVs) and patient populations.  In addition to its permanent staff, CTI CRC has a sizable pool of as-needed personnel including physicians, pharmacists, skilled nurses, emergency medical technicians (EMTs), paramedics, phlebotomists, and a team of experts in clinical pharmacology, pharmacokinetics (PK), and drug metabolism.

Patient Recruitment

The CTI CRC has a dedicated subject recruitment and patient marketing department.  Since the onset of the pandemic, the team has significantly accelerated recruiting efforts to prepare for COVID-19 therapeutic and vaccine programs.

  • Proactively reaching out to individuals from our extensive patient database to pre-identify individuals interested in participating in a COVID-19 trial.  CTI CRC currently has over 3,000 subjects with confirmed interest pre-identified and ready to enroll in a COVID-19 vaccine program and expects this number to be upwards of 10,000 subjects over the next few months.
  • Started geo-targeted advertising in the area to reach the general public. Currently running multiple types of traditional and digital advertising, which can be scaled up or expanded at any time to increase the patient pool beyond the current database.

If you would like to learn more about including the CTI CRC as a site on your COVID-19 program, fill out the form below and a member of our team will be in touch within a few business days.